UPMC Hillman Cancer Center | Strategic Alliance Partners

In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.

Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.

The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Results from a four-year follow-up of a phase 3 trial determined that the combination of Imbruvica and Venclexta provided benefits for untreated patients with CLL.

Depression reduces the likelihood of receiving recommend treatment, which can affect survival, according to a Kentucky-based study of patients with breast cancer.